These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1120 related articles for article (PubMed ID: 24380394)

  • 21. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
    He M; Yokota T
    Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
    Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
    Maruyama R; Aoki Y; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.
    Yin H; Betts C; Saleh AF; Ivanova GD; Lee H; Seow Y; Kim D; Gait MJ; Wood MJ
    Mol Ther; 2010 Apr; 18(4):819-27. PubMed ID: 20068555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
    Popplewell LJ; Graham IR; Malerba A; Dickson G
    Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
    Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
    Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
    Yin H; Moulton HM; Betts C; Seow Y; Boutilier J; Iverson PL; Wood MJ
    Hum Mol Genet; 2009 Nov; 18(22):4405-14. PubMed ID: 19692354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and application of bispecific splice-switching oligonucleotides.
    Bestas B; McClorey G; Tedebark U; Moreno PM; Roberts TC; Hammond SM; Smith CI; Wood MJ; Andaloussi SE
    Nucleic Acid Ther; 2014 Feb; 24(1):13-24. PubMed ID: 24506779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.
    Aartsma-Rus A; van Ommen GJ
    RNA; 2007 Oct; 13(10):1609-24. PubMed ID: 17684229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induced dystrophin exon skipping in human muscle explants.
    McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
    Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].
    Takeda S
    Rinsho Shinkeigaku; 2009 Nov; 49(11):856-8. PubMed ID: 20030230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
    Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R
    Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
    Mitrpant C; Fletcher S; Iversen PL; Wilton SD
    J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
    Aoki Y; Yokota T; Nagata T; Nakamura A; Tanihata J; Saito T; Duguez SM; Nagaraju K; Hoffman EP; Partridge T; Takeda S
    Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13763-8. PubMed ID: 22869723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview on DMD exon skipping.
    Aartsma-Rus A
    Methods Mol Biol; 2012; 867():97-116. PubMed ID: 22454057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exon skipping: a first in class strategy for Duchenne muscular dystrophy.
    Niks EH; Aartsma-Rus A
    Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.